Table 1 Antibacterial sensitivity profile of the MDR clinical P. aeruginosa
Antibiotic | LSI resistance breakpoint (mm) | Sensitivity (%) | Intermediate sensitivity (%) | Resistance (%) |
|---|---|---|---|---|
1 Ampicillin | ≤ 13 | 0 | 0 | 100 |
2 Ampicillin/Sulbactam | ≤ 11 | 0 | 0 | 100 |
3 Cefotaxime | ≤ 14 | 0 | 5 | 95 |
4 Cefoxitin | ≤ 14 | 0 | 3 | 97 |
5 Cefpodoxime | ≤ 17 | 0 | 0 | 100 |
6 Ceftazidime | ≤ 14 | 91 | 4 | 5 |
7 Cefuroxime | ≤ 14 | 0 | 0 | 100 |
8 Cefuroxime/Axetil | ≤ 14 | 0 | 0 | 100 |
9 Ciprofloxacin | ≤ 15 | 83 | 0 | 17 |
10 Gentamycin | ≤ 15 | 38 | 43 | 19 |
11 Imipenem | ≤ 13 | 95 | 5 | 0 |
12 Levofloxacin | ≤ 13 | 82 | 0 | 18 |
13 Meropenem | ≤ 15 | 98 | 2 | 0 |
14 Nitrofurantoin | ≤ 13 | 95 | 0 | 5 |
15 Piperacillin | ≤ 14 | 20 | 67 | 13 |
16 Piperacillin/Tazobactam | ≤ 14 | 17 | 70 | 13 |
17 Tetracycline | ≤ 11 | 5 | 0 | 95 |
18 Tobramycin | ≤ 12 | 85 | 0 | 15 |
19 Trimethoprim/sulfamethoxazole | ≤ 10 | 5 | 0 | 95 |